SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition

Considering that COVID-19 could adversely affect cancer patients, several countries have prioritized this highly susceptible population for vaccination. Thus, rapidly generating evidence on the efficacy of SARS-CoV-2 vaccination in the subset of patients with cancer under active therapy is of paramo...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Michalis Liontos, Oraianthi Fiste, Flora Zagouri, Alexandros Briasoulis, Aimilia D. Sklirou, Christos Markellos, Efthymia Skafida, Alkistis Papatheodoridi, Angeliki Andrikopoulou, Konstantinos Koutsoukos, Maria Kaparelou, Vassiliki A. Iconomidou, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
SARS-CoV-2
vaccination
cancer
immune checkpoint inhibitors
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/14/11/2796

Internet

https://www.mdpi.com/2072-6694/14/11/2796

Similar Items